CheckMate914

BMS joins Roche on the adjuvant kidney cancer flop list

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet

Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions - IOS Press

Enrique Grande on LinkedIn: Adjuvant Therapy for Renal Cell Carcinoma: A Systematic Review of Current…

A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)

ASCO 2020: A Phase III, Randomized, Placebo-Controlled Trial of Nivolumab or Nivolumab plus Ipilimumab in Patients with Localized Renal Cell Carcinoma at High-Risk of Relapse after Radical or Partial Nephrectomy (CheckMate 914)

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials - ScienceDirect

Enrique Grande on LinkedIn: #immunotherapy

Singer

Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC

CheckMate914